Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 154Gynecologic 10Sarcoma 6Genitourinary 5Endocrine 4CNS 4Thoracic 2Gastrointestinal 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1Other 1NET 1Lymphoid 1Head & Neck 1

Conditions

Hodgkin Disease 1Breast Neoplasms 1

Interventions

Rituximab 702Cyclophosphamide 645Vincristine 353Doxorubicin 309Etoposide 305Cytarabine 271Filgrastim 250Prednisone 249Methotrexate 241fludarabine phosphate 231Dexamethasone 209fludarabine 184Peripheral Blood Stem Cell Transplantation 166Radiotherapy 161Granulocyte Colony-Stimulating Factor 145Lenalidomide 144Bendamustine Hydrochloride 142Bortezomib 127Melphalan 126ibrutinib 111Busulfan 111Mycophenolic Acid 108Whole-Body Irradiation 107Tacrolimus 96Cyclosporine 87Gemcitabine 82Ifosfamide 80Calcium Dobesilate 80Alemtuzumab 80Leucovorin 78

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Tamoxifen × Lymphoid × Clear all
NCT00165308 2014-07-09

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

Dana-Farber Cancer Institute

Phase NA Completed
29 enrolled
BreastLymphoid

Breast Neoplasms, Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡